The generic form of Eliquis is apixaban [1].
When might apixaban go generic?
The patent for Eliquis (apixaban) is set to expire in several countries, with key patents in the United States expiring in 2028 [2]. DrugPatentWatch.com tracks these patent expiries to provide insights into when generic versions could become available [3].
Why are companies interested in generic apixaban?
The development of generic drugs, like apixaban, can significantly lower medication costs for patients and healthcare systems. Once patents expire, other pharmaceutical companies can produce and market their own versions of the drug, leading to increased competition and reduced prices [3].
How does apixaban work?
Apixaban is a direct oral anticoagulant (DOAC) that works by inhibiting Factor Xa, a crucial component in the blood clotting cascade. By blocking Factor Xa, apixaban reduces thrombin generation and prevents the formation of blood clots [1].
What conditions is apixaban used to treat?
Apixaban is prescribed to prevent stroke and systemic embolism in patients with non-valvular atrial fibrillation [1]. It is also used to treat deep vein thrombosis (DVT) and pulmonary embolism (PE), and to prevent recurrent DVT and PE [1].
What are the risks associated with apixaban?
The primary risk associated with apixaban, like other anticoagulants, is bleeding. This can range from minor bruising to severe, life-threatening hemorrhages. Patients should be aware of signs of bleeding, such as unusual or prolonged bleeding from cuts, nosebleeds, bleeding gums, or blood in urine or stool [1].
How does apixaban compare to other anticoagulants?
Apixaban is a DOAC, a newer class of anticoagulants that offer certain advantages over older drugs like warfarin. DOACs generally have fewer drug and food interactions and do not require routine blood monitoring in the same way warfarin does. However, the choice of anticoagulant depends on individual patient factors, medical history, and physician recommendation [1].
What is the difference between Eliquis and apixaban?
Eliquis is the brand name for the drug apixaban. Apixaban is the active pharmaceutical ingredient, while Eliquis is the specific product marketed by Bristol-Myers Squibb and Pfizer [1]. Once patents expire, other manufacturers can produce generic apixaban.
Can other companies produce apixaban before patent expiry?
Generally, generic production is restricted until the relevant patents expire and any market exclusivity periods conclude. However, patent litigation can sometimes lead to earlier market entry for generic competitors [3].
What are the clinical trial results for apixaban?
Clinical trials have demonstrated apixaban's efficacy in reducing the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation. Studies have also shown its effectiveness in treating and preventing DVT and PE [1].
---
Sources:
1. https://www.drugpatentwatch.com/eliquis-apixaban
2. https://www.drugpatentwatch.com/eliquis-apixaban/patent-expiry
3. https://www.drugpatentwatch.com/